← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일

현재 선택: 1개 · 임상 갱신 필요 1개

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

API CSV14행 · 1개 프로그램
OverviewToxicologyClinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
AntibodyLimited DatastalePreclinical
nivolumab (Opdivo, HNSCC patients have used Nivolumab)
Chang Gung Memorial Hospital·HNSCC
1 trials
Overview
Program
HNSCC patients have used Nivolumab
Overview
Company
Chang Gung Memorial Hospital
Overview
Modality
ANTIBODY
Overview
Target
HNSCC
Overview
Indication
HNSCC
Overview
Phase
PRECLINICAL
Overview
Status
ACTIVE
Overview
Content status
Limited Data
Overview
Data Confidence
Data Confidence · Low
Overview
Development Signal
Development Signal · Watch
Overview
Approval status
Investigational
Toxicology
Major finding
Anti-EGFR plus anti-PD1 in advanced and refractory cutaneous squamous cell carcinoma: a cohort study.. Advanced cutaneous squamous cell carcinoma (cSCC) is associated with a poor prognosis. Although anti-Programmed cell Death protein 1 (anti-PD1) immunotherapy has improved cSCC management, its efficacy remains limited in some patients. Second-line options, including anti-epidermal growth fact…
Clinical
Safety signal
Anti-EGFR plus anti-PD1 in advanced and refractory cutaneous squamous cell carcinoma: a cohort study.. Advanced cutaneous squamous cell carcinoma (cSCC) is associated with a poor prognosis. Although anti-Programmed cell Death protein 1 (anti-PD1) immunotherapy has improved cSCC management, its efficacy remains limited in some patients. Second-line options, including anti-epidermal growth fact…
Clinical
Program phase
PRECLINICAL